NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

NCT02673710

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Metastatic Colorectal Cancer

Interventions: No intervention

Countries: Belgium

The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients treated in first line with bevacizumab for whom it is decided, and who are clinically considered eligible, to continue the treatment with bevacizumab beyond PD1.
* Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment.
* Availability of specific retrospective data at diagnosis and during 1st line treatment

Exclusion Criteria:

* Patients who are participating or participated in first line in any other interventional clinical trial involving non-standard of care procedures impacting the body composition
* Dementia or another mental condition making it impossible to fill out questionnaires

Locations (23)

Aalst, Belgium
Assebroek, Belgium
Auderghem, Belgium
Bonheiden, Belgium
Brasschaat, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Brussels, Belgium
Charleroi, Belgium
Ghent, Belgium
Hasselt, Belgium
Leuven, Belgium
Liège, Belgium
Liège, Belgium
Mechelen, Belgium
Montigny-le-Tilleul, Belgium
Ostend, Belgium
Roeselare, Belgium
Ronse, Belgium
Sint-Niklaas, Belgium
Turnhout, Belgium
Verviers, Belgium